| Literature DB >> 23164047 |
Michail Varras1, Theodora Griva, Vasileios Kalles, Christodoulos Akrivis, Nikolaos Paparisteidis.
Abstract
BACKGROUND: The purpose of the study was to determine the incidence of gene expression of Oct-4 and DAZL, which are typical markers for stem cells, in human granulosa cells during ovarian stimulation in women with normal FSH levels undergoing IVF or ICSI and to discover any clinical significance of such expression in ART.Entities:
Year: 2012 PMID: 23164047 PMCID: PMC3536594 DOI: 10.1186/1757-2215-5-36
Source DB: PubMed Journal: J Ovarian Res ISSN: 1757-2215 Impact factor: 4.234
Figure 1mRNA sequences for Oct-4 genes. Sense and antisense mRNA sequences for Oct-4; (Tm: Melting temperature).
Figure 2mRNA sequences for DAZL genes. Sense and antisense mRNA sequences for DAZL genes; (Tm: Melting temperature).
Patient characteristics
| Infertility duration (years) | 4.00 (3.00–6.50) |
| Serum LH (IU/L) | 4.60 (3.36–8.40) |
| Total gonadotropin dose (IU) | 2,875.00 (2,037.50–3,587.50) |
| Duration of stimulation (days) | 10.00 (9.00-11.00) |
| Serum estradiol on the 5th day of rFSH administration (pg/ml) | 500.00 (309.00 – 758.00) |
| Serum estradiol on the day of hCG administration (pg/ml) | 1,910.00 (1,570.00–2,467.00) |
| Number of follicles aspirated | 8.00 (6.00-10.00) |
| Grade 2 embryos | 0.00 (0.00-2.00) |
| Grade 3 embryos | 4.00 (4.00-6.00) |
| High quality embryo ratio (%) | 100.00 (66.67 – 100.00) |
Patients’ demographics and clinical parameters.
Oct-4 expression – baseline characteristics and outcomes
| | |||
|---|---|---|---|
| Infertility Cause | | | 0.864 |
| 4 (36.4) | 4 (40.0) | | |
| 7 (63.6) | 6 (60.0) | | |
| Previous IVF/ICSI cycles | | | 0.525 |
| 9 (81.8) | 7 (70.0) | | |
| 2 (18.2) | 3 (30.0) | | |
| Embryos grade | | | 0.296 |
| 9 (81.8) | 5 (50.0) | | |
| 1 (9.1) | 3 (30.0) | | |
| 1 (9.1) | 2 (20.0) | | |
| Positive pregnancy test | | | 0.269 |
| 9 (81.8) | 6 (60.0) | | |
| 2 (18.2) | 4 (40.0) | | |
| Clinical pregnancy | | | 0.916 |
| 9 (81.8) | 8 (80.0) | | |
| 2 (18.2) | 2 (20.0) | ||
*Statistical Test.
Presence or absence of Oct-4 mRNA expression in correlation with the patients’ baseline characteristics and the outcomes from the assisted reproduction technologies.
Oct-4 expression – cycle characteristics
| Age (ys) | 36.00 (35.00, 38.00) | 36.00 (30.00, 37.00) | 0.520 |
| BMI | 23.20 (19.80, 24.60) | 22.80 (20.10, 26.30) | 0.778 |
| Serum FSH (IU/L) | 6.30 (5.80, 7.50) | 5.90 (4.30, 8.10) | 0.545 |
| SerumLH (IU/L) | 4.50 (3.40, 4.60) | 5.70 (3.40, 9.70) | 0.165 |
| SerumPRL (ng/ml) | 11.40 (9.70, 15.30) | 10.40 (5.50, 25.10) | 0.790 |
| Total gonadotropin dose | 2,675.00 (1800.0, 3200.0) | 3,112.50 (2325.00, 3675.00) | 0.364 |
| Duration of stimulation (ds) | 10.00 (9.00, 11.00) | 10.00 (9.00, 11.00) | 1.000 |
| Serum estradiol on the 5th day of rFSH administration (pg/ml) | 500.00 (350.00, 758.00) | 455.00 (180.00, 890.00) | 0.805 |
| Serum estradiol on the day of hCG administration (pg/ml) | 1,800.00 (1,200.00, 2,025.00) | 2,283.50 (1,828.00, 2,617.00) | 0.149 |
| No of follicles aspirated | 8.00 (6.00, 10.00) | 8.50 (6.00, 10.00) | 0.972 |
| No of oocyte retrieved | 8.00 (6.00, 9.00) | 8.00 (6.00, 10.00) | 0.887 |
| Mature oocytes ratio (%) | 75.00 (67.00, 80.0) | 68.5 (67.0, 78.0) | 0.415 |
*Statistical Test.
Presence or absence of Oct-4 mRNA expression in correlation with the patients’ cycle characteristics.
Figure 3Levels of Oct-4 expression and FSH levels. There is a trend for negative correlation between Oct-4 mRNA expression levels and the FSH basal levels, however it did not reach statistical significance (Spearman’s rho=−0.614, p= 0.059).
Figure 4Levels of Oct-4 expression and peak estradiol levels. There is a statistical non-significant trend for positive correlation between Oct-4 mRNA expression levels and the estradiol peak levels after hCG administration (Spearman’s rho=0.588, p=0.074).
Embryo grade – cycle characteristics
| Age (years) | 36.00 (35.00, 37.00) | 37.00 (33.00, 39.50) | 33.00 (27.00, 37.00) | 0.462 |
| FSH (IU/L) | 6.00 (4.90, 6.80) | 7.60 (4.50, 11.40) | 6.30 (6.10, 8.10) | 0.607 |
| PRL (ng/mL) | 11.40 (9.30, 15.90) | 6.00 (3.60, 21.90) | 13.80 (4.90, 16.10) | 0.581 |
| Total gonadotropin dosage | 2,700.00 (2,275.00, 3,150.00) | 2,387.00 (1,525.00, 3,300.00) | 4,000.00 (3,675.00, 4,050.00) | 0.029 |
| Serum estradiol, 5th day of rFSH administration (pg/mL) | 546.50 (450.00, 933.00) | 455.00 (250.50, 633.50) | 157.00 (63.00, 309.00) | 0.040 |
| Serum estradiol peak (pg/mL) | 1,967.50 (1,700.00, 2,467.00) | 2,182.50 (1,385.00, 2,800.00) | 1,828.00 (1,023.00, 2,022.00) | 0.556 |
| Number of oocytes retrieved | 8.00 (6.00, 9.00) | 8.50 (6.00, 10.50) | 8.00 (4.00, 9.00) | 0.713 |
| Mature oocyte ratio (%) | 71.00 (67.00, 78.00) | 75.00 (63.50, 85.50) | 75.00 (50.00, 78.00) | 0.887 |
| Oct-4/G6PD | 0.10 (0.10, 98.20) | 10.20 (3.10, 628.60) | 0.20 (0.00, 0.40) | 0.280 |
*Statistical Test.
Embryo grade in correlation with patients’ cycle characteristics and levels of Oct-4/G6PD genes expression.
Clinical pregnancy – cycle characteristics
| Age (years) | 36.00 (33.00, 37.00) | 37.50 (35.50, 41.50) | 0.238 |
| FSH (IU/L) | 6.30 (5.60, 8.00) | 4.20 (3.80, 5.50) | 0.065 |
| PRL (ng/mL) | 10.00 (7.10, 15.30) | 16.80 (11.40, 25.10) | 0.137 |
| Total gonadotropin dosage | 2,987.50 (2,037.50, 3,662.50) | 2,512.00 (1,725.00, 3,112.50) | 0.345 |
| Serum estradiol, 5th day of rFSH administration (pg/mL) | 500.00 (309.00, 758.00) | 503.50 (403.50, 729.50) | 0.754 |
| Serum estradiol, peak (pg/mL) | 1,845.00 (1,570.00, 2,317.00) | 2,188.50 (1,466.50, 2,636.00) | 0.687 |
| Number of oocytes retrieved | 7.00 (6.00, 90.00) | 9.00 (7.50, 9.50) | 0.468 |
| Mature oocyte ratio (%) | 75.00 (67.00, 78.00) | 68.50 (67.00, 76.50) | 0.719 |
| Oct-4/G6PD | 0.30 (0.10, 58.80) | 54.20 (10.20, 98.20) | 0.296 |
*Statistical Test.
Clinical pregnancy in correlation with patients’ cycle characteristics and levels of Oct-4/G6PD genes expression.